AU2019377552B2 - Treatment and diagnosis of autoantibody-mediated eye diseases - Google Patents

Treatment and diagnosis of autoantibody-mediated eye diseases

Info

Publication number
AU2019377552B2
AU2019377552B2 AU2019377552A AU2019377552A AU2019377552B2 AU 2019377552 B2 AU2019377552 B2 AU 2019377552B2 AU 2019377552 A AU2019377552 A AU 2019377552A AU 2019377552 A AU2019377552 A AU 2019377552A AU 2019377552 B2 AU2019377552 B2 AU 2019377552B2
Authority
AU
Australia
Prior art keywords
acpa
disease
ocular
eye
ocular surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019377552A
Other languages
English (en)
Other versions
AU2019377552A1 (en
Inventor
Sandeep Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois at Urbana-Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana-Champaign, University of Illinois System filed Critical University of Illinois at Urbana-Champaign
Publication of AU2019377552A1 publication Critical patent/AU2019377552A1/en
Application granted granted Critical
Publication of AU2019377552B2 publication Critical patent/AU2019377552B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019377552A 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases Active AU2019377552B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862757641P 2018-11-08 2018-11-08
US62/757,641 2018-11-08
US201962855253P 2019-05-31 2019-05-31
US62/855,253 2019-05-31
PCT/US2019/060566 WO2020097528A1 (en) 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases

Publications (2)

Publication Number Publication Date
AU2019377552A1 AU2019377552A1 (en) 2021-05-27
AU2019377552B2 true AU2019377552B2 (en) 2026-07-23

Family

ID=69056109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019377552A Active AU2019377552B2 (en) 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases

Country Status (10)

Country Link
US (1) US20220062337A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877406A1 (cg-RX-API-DMAC7.html)
JP (2) JP7624220B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210093274A (cg-RX-API-DMAC7.html)
CN (1) CN113631570B (cg-RX-API-DMAC7.html)
AU (1) AU2019377552B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008548A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118367A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005352A (cg-RX-API-DMAC7.html)
WO (1) WO2020097528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100002306A1 (it) * 2021-02-03 2022-08-03 Univ Degli Studi Roma La Sapienza Procedimento e kit per la diagnosi in vitro della sindrome da anticorpi anti-fosfolipidi
US11951123B2 (en) * 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
WO2023201283A2 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Methods of producing plasma or serum and uses thereof
WO2024077068A1 (en) * 2022-10-06 2024-04-11 Oklahoma Medical Research Foundation Anti-vimentin antibodies are associated with higher severity of sjögren's syndrome
WO2024136368A1 (ko) * 2022-12-21 2024-06-27 건국대학교 산학협력단 α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984492B2 (en) 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
CA2888519C (en) 2012-10-17 2023-02-21 Liverpool School Of Tropical Medicine Immunomodulatory proteins
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sanchez-Avila et al., 2017, The Effect of Immunologically Safe Plasma Rich in Growth Factor Eye Drops in Patients with Sjo¨gren Syndrome, JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS Volume 33, Number 5, pages 391-399 (Year: 2017) *

Also Published As

Publication number Publication date
WO2020097528A1 (en) 2020-05-14
US20220062337A1 (en) 2022-03-03
MX2021005352A (es) 2021-09-14
KR20210093274A (ko) 2021-07-27
AU2019377552A1 (en) 2021-05-27
CA3118367A1 (en) 2020-05-14
BR112021008548A2 (pt) 2021-08-03
EP3877406A1 (en) 2021-09-15
JP2022512946A (ja) 2022-02-07
CN113631570B (zh) 2026-06-02
JP2025061211A (ja) 2025-04-10
CN113631570A (zh) 2021-11-09
JP7624220B2 (ja) 2025-01-30